Neurological and chest symptoms following sclerotherapy: a single centre experience.
OBJECTIVE
Documentation and analysis of adverse neurological and chest symptoms in a large single centre series of sclerotherapy treatments.


METHODS
In this retrospective study, patient-reported adverse events occurring during liquid or foam sclerotherapy were recorded over a 30 month period and subsequently analyzed. The relevant patient records were reviewed to determine patient characteristics, treatment details and results of subsequent investigations.


RESULTS
A total of 1744 ultrasound guided sclerotherapy treatments were performed during the study period. Almost all treatments were done with air-based sodium tetradecyl sulphate foam. During the same time period, 6504 direct vision surface vein sclerotherapy treatments were completed. Approximately 1/4 of these utilized air-based foam in varying concentrations. There were 14 adverse events in 14 patients involving neurological or chest symptoms for an incidence of 0.17%. Five patients injected with foam complained of isolated chest discomfort, tightness or shortness of breath. Nine patients reported various brief neurological symptoms. These events occurred with both liquid and foam, although the majority involved foam. More neurological events were associated with direct vision sclerotherapy of smaller superficial veins than with ultrasound guided injection of intrafascial truncular veins. Seven patients who experienced neurological symptoms had a history of migraine. Five of the patients who had neurological events were investigated for right to left shunts and found to be positive.


CONCLUSIONS
These events were uncommon and brief. The incidence of neurological and chest symptoms was higher with foam sclerotherapy than with liquid. A history of migraine with aura was associated with an increased risk of post-treatment neurological symptoms. Events occurred with both large vein and small vein treatment. Some events were associated with liquid sclerotherapy rather than foam and with carbon dioxide based foam as well as air foam. There were no long-term adverse consequences.
The Vein Treatment Centre, Calgary, Alberta, Canada douglashill@shaw.ca.
Douglas A
DA
Hill
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000388:Air; D002245:Carbon Dioxide / Q000009:adverse effects; D002637:Chest Pain / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000209:etiology; D009422:Nervous System Diseases / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D012501:Saphenous Vein / Q000473:pathology; D012597:Sclerosing Solutions / Q000009:adverse effects* / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects* / Q000379:methods*; D012981:Sodium Tetradecyl Sulfate / Q000737:chemistry; D014648:Varicose Veins / Q000628:therapy; D055815:Young Adult
D012597:Sclerosing Solutions; D002245:Carbon Dioxide; D012981:Sodium Tetradecyl Sulfate
Foam; chest; complications; neurological; safety; sclerotherapy